On July 26, the medical network was promoted, and the business market of east China pharmaceutical was on the rise.
▍ three pharmaceutical business owners
Nanjing medicine will be next.
Yesterday (25), nanjing medicine notice announced that the company intends to acquire the three remaining equity holdings subsidiary, including jiangsu huaxiao pharmaceutical logistics co., LTD. (19.9995%), nanjing medicine, nantong jianqiao pharmaceutical co., LTD. (20%), nanjing (huaian) day h co., LTD. (39.84%), the transferee total price is 95.7984 million yuan
On March 26, 2013, nanjing medical had just bought back 64.12% of nanjing medical nantong jianqiao co., LTD. On the evening of July 25, 2017 nanjing medicine announced that once again the transferee nanjing medicine nantong co., LTD. 20% stake in Cambridge, so far with the other two subsidiary companies, nanjing pharmaceutical finished 100% stake held for three subsidiaries.
However, after four years of this equity and asset consolidation, it is the demand of the pharmaceutical logistics enterprises to improve the concentration degree.
▍ medicine distribution in the north of the three companies
After the completion of the stake, nanjing pharmaceutical will directly own 100% of the three companies.
Nanjing medicine, said the three subsidiaries to accept the transfer, all bear the important business - plus three subsidiaries in north jiangsu business performance in recent years, continue to improve, acquisition can increase the company's main business core assets, further enhance profitability.
According to the announcement, jiangsu huachong pharmaceutical logistics co., LTD., nanjing pharmaceutical co., LTD., has a total assets of 478 million yuan. The main proprietary Chinese medicine, chemical medicine preparations, chemical pharmaceuticals, antibiotics, biochemical drugs, biological products, psychotropic drugs (class 2), one, two, three types of medical equipment, sanitary materials, vaccines, etc. It provides pharmaceutical products with basic national drug, OTC and medical insurance drugs as the main products.
Not only that, in fact, from 2008 to 2008, jiangsu huaxiao pharmaceutical logistics co., LTD., achieve business income is 8.8027 billion yuan, is currently in north jiangsu throughput, one of the largest pharmaceutical logistics enterprises in yancheng axis of logistics distribution radius around the radiation in jiangsu province, and extended to zhejiang, anhui, henan, fujian market.
Founded in May 1956, nanjing medical nantong jianqiao co., ltd. is also a history of more than 60 years, and in July 2002, it became nanjing pharmaceutical holding subsidiary. The main business is pharmaceutical logistics distribution, jianqiao company is the mainstream drug delivery enterprise in nantong region, and the main business revenue in 2015 is nearly 1 billion yuan.
Nanjing medicine day h (huaian) co., LTD. Is the original huaiyin YiYaoZhan, huaiyin medicine station merger restructuring, nanjing pharmaceutical investment holding, the largest in north jiangsu medicine circulation enterprises, the 2012 annual sales of 1.4 billion yuan.
It is not hard to see that nanjing pharma, the regional faucet, is extending its reach to a wider range of control through the way of "compiling" local powerful pharmaceutical businesses.
▍ assets integration policy challenges
In fact, in 2013, in order to solve the problem of weak profitability of the company, nanjing medicine had frequent asset consolidation movements.
Nanjing medicine in November 2013, and jinling pharmaceutical industry Big shareholders nanjing jinling pharmaceutical group on a scale of 75 million yuan of asset replacement, nanjing medicine and jinling pharmaceutical belong to medicine industry group, the medicine circulation and pharmaceutical industry listed platform.
Since early 2013, nanjing medicine several times to disposal of assets, including transfer of nanjing tongrentang (huangshan) international health industry management, fuzhou rejuvenation Chinese medicine yinpian factory, hefei home Beijing, Chinese medicine yinpian co., LTD., etc., as well as the transferee nanjing pharmaceutical co., LTD., nantong health bridge stake in medicine and medical supplies co., LTD.
Analysis shows that nanjing medicine this refusal under three subsidiary, with the integration of assets since 2013, the purpose of action have almost the same that is accelerating the pace of nanjing medicine integration of assets, and eliminate the competition.
Nanjing medical part of the rest three subsidiaries, the transfer is in advocate business wu income all around billion, are areas in the north of the drug distribution, pharmaceutical logistics enterprises and business areas overlap to a certain extent, certainly will have some competition. This situation not only dilutes the profit value of the drug delivery market, but also a waste of the company's capacity.
Complete the transferee, owns a 100% stake in the three subsidiaries, will enable the company's internal distribution of the resources assigned to a new integration, enhance the capacity of the company as a whole region distribution, making nanjing pharmaceutical on drug distribution to further strengthen the ability of dealing with two votes environment, to the requirement of higher pharmaceutical distribution enterprises.
The stake is not only a lonely choice of nanjing medicine, but it will also be a necessary way for some pharmaceutical logistics companies. |
